Evidence map›Paper›PMID 40760260›Full record

ArticleDiscover oncology2025

Co-administration of nobiletin and tetrahydrocurcumin enhanced the cytotoxicity to breast cancer through inhibiting CYP1A1 enzyme: from the perspective of pharmacokinetic interactions.

Hongming Song, Fengqin Gao, Zhaohe Niu, Xiangping Liu, Xingang Wang, Weihong Cao, Haibo Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hongming SongBreast Disease Center, The Affiliated Hospital of Qingdao University, No 59 Haier Rd, Qingdao, 266000, Shandong, China. hongmingsong@qdu.edu.cn.
Fengqin GaoDepartment of Oncology Center 3, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong, China.
Zhaohe NiuBreast Disease Center, The Affiliated Hospital of Qingdao University, No 59 Haier Rd, Qingdao, 266000, Shandong, China.
Xiangping LiuMedical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Xingang WangBreast Disease Center, The Affiliated Hospital of Qingdao University, No 59 Haier Rd, Qingdao, 266000, Shandong, China.
Weihong CaoBreast Disease Center, The Affiliated Hospital of Qingdao University, No 59 Haier Rd, Qingdao, 266000, Shandong, China.
Haibo WangBreast Disease Center, The Affiliated Hospital of Qingdao University, No 59 Haier Rd, Qingdao, 266000, Shandong, China. hbwang66@qdu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

objectivesThe introduction of traditional Chinese medicine to the treatment of breast cancer increases the risk of adverse herb-herb interactions. Both nobiletin and tetrahydrocurcumin (THC) have been demonstrated to inhibit breast cancer progression, which makes them easily co-prescribed. This study evaluated the co-administration of nobiletin and THC, aiming to assess their synergistic effect in inhibiting breast cancer and reveal the potential mechanism. MATERIALS &

methodsA single dosage of nobiletin and its co-administration with THC were performed in rats. The pharmacokinetic profiling of nobiletin was analyzed under the two administration strategies. Rat liver microsomes were employed for evaluating the metabolic stability of nobiletin and the activity of CYP1A1 with the probe-substance assay. The cytotoxicity of nobiletin and its combination with THC was evaluated in MCF-7 cells with the help of the CCK8 assay.

resultsCo-administration strategy significantly changed the pharmacokinetics of nobiletin with the increasing Cmax (187.00 ± 9.27 vs. 145.87 ± 8.16 mg/L), prolonging t

conclusionCo-administration of nobiletin with THC increased its systemic exposure and enhanced its cytotoxicity to breast cancer. The inhibited activity of CYP1A1 was considered the underlying mechanism of their interaction.

Indexed as

Co-administrationCYP450CytotoxicityDrug-drug interactionPharmacokineticSynergistic effect

Identifiers

PMID40760260
PMCPMC12321715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.